Duration of Action of 2 Insulin Glargine Products, LY2963016 and Lantus®, in Subjects with Type I Diabetes Mellitus (T1DM)

被引：0
|
作者：
Heise, Tim
Zhang, Xin
Lam, Eric Chen Quin
Seger, Mary E.
Coutant, David
Chua, Laiyi
Linnebjerg, Helle
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
891-P
引用
收藏
页码：A228 / A228
页数：1
相关论文
共 50 条
  • [21] Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with type 2 diabetes mellitus: the ELEMENT 2 study
    Hollander, P.
    Rosenstock, J.
    Bhargava, A.
    Ilag, L. L.
    Pollom, R. K.
    Huster, W. J.
    Prince, M. J.
    DIABETOLOGIA, 2014, 57 : S388 - S388
  • [22] Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with type 1 diabetes mellitus: the ELEMENT 1 study
    Pollom, R. K.
    Blevins, T.
    Dahl, D.
    Rosenstock, J.
    Huster, W. J.
    Ilag, L. L.
    Prince, M. J.
    DIABETOLOGIA, 2014, 57 : S69 - S69
  • [23] Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial
    Yan, Xiang
    Jiang, Shan
    Lou, Ying
    Zhou, Zhiguang
    DIABETES OBESITY & METABOLISM, 2021, 23 (10): : 2226 - 2233
  • [24] The efficacy and safety of LY2963016 among patients with Type 1 and Type 2 diabetes previously treated with insulin glargine
    Asaro-Harris, A.
    Dahl, D.
    Lacaya, L. B.
    Pollom, R. K.
    Ilag, L. L.
    Zielonka, J. S.
    Hadjiyanni, I.
    DIABETIC MEDICINE, 2015, 32 : 168 - 168
  • [25] LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes (vol 32, pg 91, 2018)
    Lamb, Yvette N.
    Syed, Yahiya Y.
    BIODRUGS, 2018, 32 (02) : 181 - 181
  • [26] Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus) in Chinese adults with type 2 diabetes: A phase III, randomized, open-label, controlled trial
    Feng, Wenhuan
    Chen, Wei
    Jiang, Shan
    Du, Liying
    Zhu, Dalong
    DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1786 - 1794
  • [27] Authors' Reply to Dr. Riccardo Perfetti: "LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes"
    Lamb, Yvette N.
    Syed, Yahiya Y.
    BIODRUGS, 2018, 32 (02) : 179 - 179
  • [28] Similar Intrapatient Blood Glucose Variability with LY2963016 and Lantus® Insulin Glargine in Patients with Type 1 (T1D) or Type 2 Diabetes, Including a Japanese T1D Subpopulation
    Hiroshi Nishiyama
    Tomotaka Shingaki
    Yumi Suzuki
    Liza L. Ilag
    Diabetes Therapy, 2018, 9 : 1469 - 1476
  • [29] Authors’ Reply to Dr. Riccardo Perfetti: “LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes”
    Yvette N. Lamb
    Yahiya Y. Syed
    BioDrugs, 2018, 32 : 179 - 179
  • [30] Comparative Pharmacokinetics (PK) and Pharmacodynamics (PD) of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus® Insulin Glargine in Healthy Subjects
    Linnebjerg, Helle
    Lam, Eric Chen Quin
    Seger, Mary E.
    Coutant, David
    Chua, Laiyi
    Chong, Chew Lan
    Ferreira, Maria M.
    Soon, Danny
    Zhang, Xin
    DIABETES, 2014, 63 : A227 - A227
12345